New diagnoses of six major cancer types fell in the early part of the pandemic, according to findings from part 2 of the latest Annual Report to the Nation on the Status of Cancer.
NCI’s Clinical Proteomic Tumor Analysis Consortium releases proteogenomic dataset to accelerate cancer discoveries.
An NCI study shows that cell division can be interrupted by withdrawing growth-promoting signals early on in the process.
NCI has awarded $50 million to establish five new centers to study interventions for improving cancer outcomes in persistent poverty communities.
ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.
A new study has outlined opportunities for achieving President Biden and First Lady Biden’s Cancer Moonshot goal of reducing the cancer death rate by at least 50% over the next 25 years.
NCI has helped launch the Pragmatica-Lung Study, a phase 3 randomized clinical trial of a two-drug combination to treat patients with advanced non-small cell lung cancer. The simplified trial design aims to increase accessibility for participants.
An NCI study shows that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a type of immunotherapy, can live for decades after diagnosis.
As part of the Cancer Grand Challenges program, NCI and Cancer Research UK have announced nine new research challenges to tackle profound problems in cancer research.
A clinical trial led by NCI has resulted in FDA approval of the immunotherapy drug atezolizumab (Tecentriq) to treat advanced alveolar soft part sarcoma.